Day One Biopharmaceuticals, Inc. financial statements, including revenue, expenses, profit, and loss

The total revenue of DAWN for the last quarter is 93.76 M USD, and it's 1044.54% higher compared to the previous quarter. The net income of Q3 24 is 37.04 M USD.